ArticleFrontiers in endocrinology2026
Serum SH2B1 and SULT1A2 in relation to adiposity and early weight-loss response: a hypothesis-generating study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Individual responses to weight loss interventions are highly heterogeneous. This study aimed to explore the association between serum SULT1A2 and SH2B1 levels and weight loss responses, with the goal of generating biologically relevant hypotheses. Methods: The first cohort consisted of 223 patients (102 normal weight, 52 overweight, and 69 obese), to assess associations of baselines SULT1A2 and SH2B1 with weight status. The second cohort included 49 eligible participants that completed a 4-week intermittent fasting-based weight management program. They were divided into greater weight loss group (weight loss ≥5% of initial body weight) and lesser weight loss group (weight loss <5%). Serum SULT1A2 and SH2B1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Results: In the first cohort, serum SULT1A2 and SH2B1 levels varied significantly across BMI groups ( Conclusions: Circulating SULT1A2 and SH2B1 vary across adiposity phenotypes, suggesting their potential involvement in energy metabolism. Baseline SH2B1 showed a male-specific exploratory association with early weight-loss response, although this finding was not independent of age and BMI. Collectively, these results support SH2B1 as a candidate peripheral marker of further investigation in larger, independent cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.